Direct Healthcare Costs Associated with Oligoarticular Juvenile Idiopathic Arthritis at a Single Center

• Authors: Amit Thakral, Emory University; Daniel Pinto, Marquette University; Michael Miller, Northwestern University Feinberg School of Medicine; Megan L. Curran, University of Colorado Anschutz Medical Campus; Marisa Klein-Gitelman, Northwestern University Feinberg School of Medicine; Dustin D. French, Northwestern University Feinberg School of Medicine
• Journal Title: International Journal of Rheumatology
• Volume: Volume 2020
• Publisher: International Journal of Rheumatology | 2020-01-01, Pages 5640425-5640425
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1155/2020/5640425
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: Oligoarticular juvenile idiopathic arthritis; inflammation

Abstract

Oligoarticular juvenile idiopathic arthritis (JIA) is a common disease in pediatric rheumatology. The management of oligoarticular JIA can result in a considerable economic burden. This study is a four-year, retrospective cost identification analysis performed to determine the annual direct cost of care for patients with oligoarticular JIA and possible predictive clinical factors. Direct healthcare costs were defined as those associated with office visits, laboratory studies, hospital admissions, joint injections, medications, infusions, radiology tests, and emergency room visits. Disease characteristics and patient information included ANA status, gender, age at diagnosis, duration from diagnosis to initial visit during the study period, and whether uveitis had been diagnosed. We identified 97 patients with oligoarticular JIA eligible for the study. The median age of diagnosis was 4.3 years. Positive ANA were noted in 75% of patients. 34% of patients received at least one intra-articular steroid injection. 32% of patients were prescribed a biologic during the study period, predominantly with other medications, while 23% of patients received only NSAIDs. 20% of patients were prescribed oral steroids. The average total direct medical cost in this study per year for an oligoarticular JIA patient was $3929±6985. Medications accounted for 85% of annual direct medical costs. Clinic visits and laboratory testing accounted for 8% and 5%, respectively. Patient characteristics and demographics were tested for association with direct medical costs by the Wilcoxon rank sum test and Kruskal-Wallis test. Patients who were ANA positive had increased annual costs compared to patients who are ANA negative. ANA-positive patients were found to have statistically significant costs, particularly, in laboratory tests, procedural costs, radiology costs, and medication costs. The results reported here provide information when allocating healthcare resources and a better understanding of the economic impact oligoarticular JIA has on the United States healthcare system.